Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obeticholic Acid in Chronic HBV with Hepatic Steatosis
NCT06691412Phase 3Not yet recruiting
- Sponsor
- Assiut University
- Start
- Nov 2024
- Primary completion
- Jan 2026
- Modality
- Orthosteric Ligands
01
Overview
Phase 3, randomised, open-label trial of obeticholic acid in hepatitis B (HBV) and hepatic steatosis (2 arms), sponsored by Assiut University. Primary endpoint: Degree of hepatic steatosis at 6 months. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
obeticholic acid
03
Conditions
hepatitis B (HBV)hepatic steatosis
Beyond the preview
Go deeper on NCT06691412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06691412.